Literature DB >> 18093978

Nuclear tumor necrosis factor receptor-associated factor 6 in lymphoid cells negatively regulates c-Myb-mediated transactivation through small ubiquitin-related modifier-1 modification.

Lan V Pham1, Hai-Jun Zhou, Yen-Chiu Lin-Lee, Archito T Tamayo, Linda C Yoshimura, Lingchen Fu, Bryant G Darnay, Richard J Ford.   

Abstract

Tumor necrosis factor receptor-associated factor 6 (TRAF6) is an adaptor/scaffold protein that mediates several important signaling pathways, including the tumor necrosis factor-R:NF-kappaB pathway, involved in immune surveillance, inflammation, etc. Because most studies of TRAF6 function have focused primarily on its role as an adaptor molecule in signaling pathways in the cytoplasm, the potential functions of TRAF6 in other cellular compartments has not been previously investigated. Here, we demonstrate that TRAF6 resides not only in the cellular cytoplasm but is also found in the nuclei of both normal and malignant B lymphocytes. TRAF6 does not possess a nuclear localization signal but enters the nucleus through the nuclear pore complex containing RanGap1. Chromatin immunoprecipitation cloning experiments demonstrated that nuclear TRAF6 associates with c-Myb within the 5'-end of the c-Myb promoter. Further analysis showed that nuclear TRAF6 is modified by small ubiquitin-related modifier-1, interacts with histone deacetylase 1, and represses c-Myb-mediated transactivation. Thus, TRAF6 negatively regulates c-Myb through a novel repressor function in the nuclei of both normal and malignant B-lymphocytes that could represent a novel control mechanism that maintains cell homeostasis and immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18093978     DOI: 10.1074/jbc.M706307200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease.

Authors:  Lan V Pham; Muychi T Vang; Archito T Tamayo; Gary Lu; Pramoda Challagundla; Jeffrey L Jorgensen; Alex A Rollo; Zhishuo Ou; Liang Zhang; Michael Wang; Richard J Ford
Journal:  Leuk Lymphoma       Date:  2014-04-29

2.  Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.

Authors:  Lan V Pham; Lingchen Fu; Archito T Tamayo; Carlos Bueso-Ramos; Elias Drakos; Francisco Vega; L Jeffrey Medeiros; Richard J Ford
Journal:  Blood       Date:  2010-10-01       Impact factor: 22.113

3.  TRAF6 is autoinhibited by an intramolecular interaction which is counteracted by trans-ubiquitination.

Authors:  Kent Z Q Wang; Deborah L Galson; Philip E Auron
Journal:  J Cell Biochem       Date:  2010-06-01       Impact factor: 4.429

4.  MYCBP2 Is a Guanosine Exchange Factor for Ran Protein and Determines Its Localization in Neurons of Dorsal Root Ganglia.

Authors:  Angela Dörr; Sandra Pierre; Dong D Zhang; Marina Henke; Sabrina Holland; Klaus Scholich
Journal:  J Biol Chem       Date:  2015-08-24       Impact factor: 5.157

5.  USP2a positively regulates TCR-induced NF-κB activation by bridging MALT1-TRAF6.

Authors:  Yi Li; Xiao He; Shuai Wang; Hong-Bing Shu; Yu Liu
Journal:  Protein Cell       Date:  2012-12-20       Impact factor: 14.870

6.  Cezanne paints inflammation by regulating ubiquitination.

Authors:  Jun-ichi Abe; Bradford C Berk
Journal:  Circ Res       Date:  2013-06-07       Impact factor: 23.213

7.  TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity.

Authors:  Tomoya Muto; Maria Guillamot; Jennifer Yeung; Jing Fang; Joshua Bennett; Bettina Nadorp; Audrey Lasry; Luna Zea Redondo; Kwangmin Choi; Yixiao Gong; Callum S Walker; Kathleen Hueneman; Lyndsey C Bolanos; Laura Barreyro; Lynn H Lee; Kenneth D Greis; Nikita Vasyliev; Alireza Khodadadi-Jamayran; Evgeny Nudler; Amaia Lujambio; Scott W Lowe; Iannis Aifantis; Daniel T Starczynowski
Journal:  Cell Stem Cell       Date:  2022-01-18       Impact factor: 25.269

Review 8.  Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity.

Authors:  Shamini Vijayakumaran; Mathew B Wong; Helma Antony; Dean L Pountney
Journal:  Biomolecules       Date:  2015-07-24

9.  Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma.

Authors:  Kung-Chao Chang; Wei-Chao Chang; Yao Chang; Liang-Yi Hung; Chien-Hsien Lai; Yu-Min Yeh; Yu-Wei Chou; Chung-Hsuan Chen
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

10.  Genetic interaction between mutations in c-Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression.

Authors:  Lawryn H Kasper; Tomofusa Fukuyama; Stephanie Lerach; Yunchao Chang; Wu Xu; Song Wu; Kelli L Boyd; Paul K Brindle
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.